Wall Street Has a Positive Opinion on ​PROCEPT BioRobotics (PRCT), Here’s Why

Core Viewpoint - PROCEPT BioRobotics Corporation (NASDAQ:PRCT) is identified as an overlooked small-cap stock with positive sentiment from Wall Street ahead of its fiscal Q4 2025 earnings report, expected on February 24, 2026, with projected quarterly revenue of approximately $372.87 million and a GAAP EPS of $1.56 [1]. Group 1: Analyst Ratings - Ryan Zimmerman from BTIG maintained a Hold rating on PROCEPT without disclosing price targets [2]. - Richard Newitter from Truist Financial reiterated a Buy rating but reduced the price target from $50 to $47 [2]. - 79% of the 14 analysts covering the stock maintain a Buy rating on PROCEPT [5]. Group 2: Market Outlook - Analysts at Truist express optimism for the MedTech sector in 2026 due to attractive valuations compared to other healthcare areas, although concerns exist that the sector may become a source rather than a destination for new healthcare investments [4]. - The 12-month average price target from Wall Street indicates more than 77% upside potential from current levels [5]. Group 3: Company Overview - PROCEPT BioRobotics is a commercial-stage company specializing in surgical robotics solutions for urology, with its flagship product being the AquaBeam Robotic System, designed for minimally-invasive urologic surgeries [5].